GlassScriptPhysician profile
Alex Khromov
NPI 1689787707
$4,540.60
in general payments reported to CMS, 2019-2025
26 companies · $794 in 2025
The $794 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $443 · 2021: $614 · 2022: $692 · 2023: $491 · 2024: $767 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,052.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,487.52 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $1,127.19 | 2019-2025 | Belbuca, Xtampza |
| Amgen INC. | $292.25 | 2019-2022 | |
| Pfizer INC. | $248.19 | 2019-2025 | |
| Lilly USA, LLC | $247.81 | 2019-2021 | |
| Bioventus LLC | $182.15 | 2020-2025 | Durolane, Xcell, Supartz Fx Sodium Hyaluronate |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.96 | 2020-2025 | Relistor |
| Teva Pharmaceuticals USA, INC. | $152.81 | 2019-2020 | |
| Biotronik Nro, INC. | $141.52 | 2025 | Prospera |
| Medtronic USA, INC. | $82.44 | 2019 | |
| Horizon Therapeutics Plc | $52.49 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $50.00 | 2021-2022 | |
| Daiichi Sankyo INC. | $47.51 | 2019 | |
| Redhill Biopharma INC. | $38.25 | 2020 | |
| Assertio Therapeutics, INC. | $33.20 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Protega Pharmaceutials INC | $29.50 | 2025 | Roxybond |
| Nevro Corp. | $26.53 | 2023 | Senza |
| Valinor Pharma, LLC | $20.05 | 2024 | Movantik |
| Fidia Pharma USA INC. | $19.54 | 2023 | Triluron, Hymovis |
| Vertex Pharmaceuticals Incorporated | $17.42 | 2025 | |
| Averitas Pharma INC. | $17.12 | 2024 | Qutenza |
| Boston Scientific Corporation | $16.20 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.95 | 2023 | Seglentis |
| Astrazeneca Pharmaceuticals LP | $13.62 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.52 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Khromov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.